TECVAYLI 90 mg/ml, solution for injection bottle, 1.7 ml
Active ingredients: TÉCLISTAMAB
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 1.7 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TECVAYLI 90 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 1,7 ml
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Oct 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
61935054CIP75509074CIP133400955090748Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉCLISTAMABsolution | 90 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.